| Revision as of 16:27, 23 December 2011 editKvng (talk | contribs)Extended confirmed users, New page reviewers108,115 edits request references. mention central serous retinopathy - see citations in target article← Previous edit | Revision as of 16:28, 23 December 2011 edit undoKvng (talk | contribs)Extended confirmed users, New page reviewers108,115 edits add wiki linkNext edit → | ||
| Line 56: | Line 56: | ||
| '''Verteporfin''' (trade name '''Visudyne'''), a benzoporphyrin derivative, is a ] used as a ] for ] to eliminate the abnormal ]s in the ] associated with conditions such as the wet form of ]. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a ] of 693 nm in the presence of ], produces highly reactive short-lived singlet oxygen and other reactive ]s, resulting in local damage to the ] and blockage of the vessels. | '''Verteporfin''' (trade name '''Visudyne'''), a benzoporphyrin derivative, is a ] used as a ] for ] to eliminate the abnormal ]s in the ] associated with conditions such as the wet form of ]. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a ] of 693 nm in the presence of ], produces highly reactive short-lived singlet oxygen and other reactive ]s, resulting in local damage to the ] and blockage of the vessels. | ||
| Verteporfin is also used off-label for the treatment of ]. | Verteporfin is also used ] for the treatment of ]. | ||
| ==Administration== | ==Administration== | ||
Revision as of 16:28, 23 December 2011
 | This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Verteporfin" – news · newspapers · books · scholar · JSTOR (Learn how and when to remove this message) |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607060 |
| Routes of administration | Intravenous |
| ATC code | |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C41H42N4O8 |
| Molar mass | 718.794 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.
Verteporfin is also used off-label for the treatment of central serous retinopathy.
Administration
Verteporfin is given intravenously, within 15 minutes before laser treatment.
Side effects
Most commonly, blurred vision. Also, photosensitivity; it is advised to avoid exposure to sunlight and unscreened lighting until 48 hours after the injection of verteporfin.
External links
| Ophthalmologicals: ocular vascular disorder agents (S01L) | |
|---|---|
| Antineovascularisation agents | |